Skip to main content
neuro42, Inc. logo

neuro42, Inc.

San Francisco, California, United StatesSee on the mapFounded 2020

  • Neuroimaging
  • Series A

neuro42 develops portable MRI technology for point-of-care neuroimaging and neurosurgical care. Its FDA 510(k)-cleared MRI system is designed for use in settings such as hospital bedsides and clinics, while its interventional MRI platform combines imaging with robotics and AI for MRI-guided surgical procedures.

Open roles
6
Raised
$28.8M
Jul 2021
Series A
Investors
7
Founded
2020

reccy insights

Recent highlights

neuro42’s most recent identified financing milestone is a $15,551,687 venture round announced on Aug 15, 2024, with Fred Moll, M.D listed as a lead investor. Earlier, the company received a $5 million grant announced on Sep 28, 2023, with the National Institute of Neurological Disorders and Stroke and Fred Moll, M.D identified as leads. Another $485,000 federal grant is dated September 2023, and a further venture financing entry on Oct 5, 2023 does not have an amount specified. These milestones complement the company’s stated work on portable neuroimaging and MRI-guided procedures. Its product positioning includes a portable MRI system described as FDA 510(k)-cleared, as well as an interventional platform combining MRI, robotics, and AI. The available milestones establish financing activity through August 2024, but do not provide later dated announcements, named partnerships, awards, or leadership changes. Accordingly, the company’s recent public profile is clearer on funding and product focus than on subsequent commercial deployments or organizational developments.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

Open roles6

What makes neuro42, Inc. distinct

  1. 01Portable MRI is designed to extend neuroimaging to bedside, clinic, and other point-of-care settings.
  2. 02Space-efficient MRI designs aim to fit into surgical environments and support flexible access to imaging.
  3. 03The interventional platform combines MRI, robotics, and AI for MRI-guided neurosurgical procedures.
  4. 04The company emphasizes patient-focused design and broader access to advanced neuroimaging.

Technology & products2

  • Portable MRI system

    FDA 510(k)-cleared MRI system designed for point-of-care neuroimaging in settings such as hospital bedsides and clinics.

  • Interventional MRI platform

    MRI-guided procedural platform integrating imaging, robotics, and AI for neurosurgical applications.

  • Portable FDA 510(k)-cleared MRI system for point-of-care neuroimaging.
  • Interventional MRI platform for MRI-guided procedures.
  • Precision robotics integrated for neurosurgical applications.
  • AI algorithms intended to support real-time surgical decision-making.

Research roots1

Labs and research groups this company came from or works with.

  • Massachusetts General HospitalBoston, United States · No page yet
    Licence
Academic data: Carter Sciences

Funding

$28.8M disclosed
  • Venture RoundAug 2024
    $15.6MLed by Fred Moll, M.D
  • Venture RoundOct 2023
    Fred Moll, M.D
  • GrantSep 2023
7 investors

Investors5

Also backed by
  • Fred Moll, M.D
  • Zepp Health
  • Zepp

Similar companies

About neuro42, Inc.

Products
Portable MRI system, Interventional MRI platform
Leadership
Michael BartholomewDinesh KumarNikhil SadhwaniAbhita Vohra
Focus areas
Medical devices, neuroimaging, MRI, neurosurgery, AI, robotics, point-of-care diagnostics, healthcare
Headquarters
San Francisco, California, United States
Founded
2020
Employees
11–50
Status
Active · private